Target Discovery is delivering the next-generation of bio/chemical tests for applications across clinical diagnostics, personalized medicine, forensics, environmental, and food & beverage analysis.
Our innovative testing strategies leverage the latest advances in analytical instrumentation, surface chemistry, microfluidics, nanotechnology, signal processing and machine learning.
We focus on users – making complexity disappear and providing affordable and accurate results, reported with clarity, speed and simplicity.
We embody the highest ethical standards, while delivering transformative value to our customers.
|Conventional Testing||TDI’s Testing|
|Equipment||Expensive lab setup with complex technologies||Single, affordable, uniquely powerful desktop instrument|
|Scale||Requires large quantities of samples and chemicals||Performed on the microscale|
|Processes||Complex steps requiring highly trained/paid staff||Simple, failsafe steps|
|Multiplexing||Each test run separately||Tests integrated into a single run on a single platform|
|Analysis Time||Slow – hours to days per test||Rapid – minutes per test|
|Sustainability||Environmentally unfriendly processes||Safe, environmentally-friendly, green processes|
|Output||Difficult to interpret results||Accurate, easy-to-interpret, reports|
We enable our customers to offer the highest quality, safe and authentic products and services at low cost.
Discover the next generation in analytical testing with Target Discovery.
Begin with micro–scale handling of the sample.
Process through a simplified and automated workflow.
Access one-step push-button analysis.
Optimize results with powerful signal processing and machine learning.
Obtain an actionable, straightforward, statistically–driven report.
Jeffrey N. Peterson, CEO, co-founded Target Discovery, Inc. and its subsidiary, Veritomyx, Inc., where he leads as Chairman & CEO. Mr. Peterson also serves as Chairman of Pressure Biosciences, Inc. (PBIO) and of Imaging3 (IGNG). His broad executive leadership experience included a career in Abbott Laboratories, as CEO & GM of Abbott South Africa, and in pivotal roles in Abbott Diagnostics. He was previously CEO of SPO&A international business development consulting, and had a career rising through General Electric’s Engineered Materials and Plastics businesses. Mr. Peterson holds BSChemE and MSChemE degrees from MIT, and he has coauthored six issued patents and multiple scientific articles. Mr. Peterson serves on the Advisory Board for the California Technology Council, served 12 years on the Board of BayBio (CA Life Sciences Association) and is Chair Emeritus of the BayBio Institute. Mr. Peterson has been an active leader in the Coalition for 21st Century Medicine and in BIO’s Personalized Medicine & Diagnostics Group. He served on the University of Texas MD Anderson Cancer Center’s Board of Advisors for the Center for Professional Development and Entrepreneurship, and continues to advise rising entrepreneurs.
Mark W. Duncan, Ph.D., Director of Application Development & Scientific Affairs, has extensive experience in mass spectrometry, clinical diagnostics and analytical chemistry. Dr. Duncan holds B.Sc. (Hons) and Ph.D. degrees from the University of New South Wales. He was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia and a Fogerty Fellow at the National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA and Saudi Arabia and has established and directed MS resources at three international institutions. He has also held senior executive positions in industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer, marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.
Adam L. Tenderholt, Ph.D., Director of Technology and Veritomyx Program, contributes substantial multidisciplinary scientific and computing expertise to Target Discovery, Inc. Dr. Tenderholt holds a Ph.D. in Physical Chemistry (Stanford University) and dual B.A. degrees in Chemistry and Integrated Science (Northwestern University). He was a postdoctoral scholar at the University of Washington where he studied proton-coupled electron transfer mechanisms using a variety of experimental and computational approaches. As a graduate student, he developed software for the processing and analysis of both experimental data (PySpline) and quantum chemical calculations (cclib and QMForge) and was responsible for the design and maintenance of a high-performance computational cluster. Dr. Tenderholt has coauthored numerous publications in high-profile peer-reviewed journals. His Journal of Computational Chemistry publication describing the cclib platform for package‐independent computational chemistry algorithms has been cited over 2,000 times. Dr. Tenderholt is a member of the American Chemical Society and the American Society for Mass Spectrometry.